• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by InspireMD Inc.

    2/14/24 4:51:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SC 13G 1 tm243309d28_sc13g.htm SC 13G

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    InspireMD, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share 

    (Title of Class of Securities)

     

    45779A846 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages 

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO. 45779A846 Page 2 of 7

     

    CUSIP No.  45779A846
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,162,392
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,162,392
    (9) Aggregate amount beneficially owned by each reporting person 2,162,392
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 45779A846 Page 3 of 7

     

    CUSIP No.  45779A846
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,162,392
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,162,392
    (9) Aggregate amount beneficially owned by each reporting person 2,162,392
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 45779A846 Page 4 of 7

     

    CUSIP No.  45779A846
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,162,392
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,162,392
    (9) Aggregate amount beneficially owned by each reporting person 2,162,392
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      InspireMD, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      4 MENORAT HAMAOR ST., TEL AVIV, L3 6744832
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, par value $0.0001 per share (the “Shares”).

     

     

     

     

     

    CUSIP NO. 45779A846 Page 5 of 7

     

     

    Item 2(e).

    CUSIP Number:
     

     

    45779A846

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

    Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 2,162,392 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 2,162,392 Shares includes 95,936 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 9.9% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 6, 2023, there were 21,549,639 Shares outstanding in addition to the 95,936 Shares issuable upon the exercise of the warrants).

     

     

     

     

    CUSIP NO. 45779A846 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
           
      (ii) Shared power to vote or to direct the vote 2,162,392
           
      (iii) Sole power to dispose or to direct the disposition of 0
           
      (iv) Shared power to dispose or to direct the disposition of 2,162,392
           
     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
           
      (ii) Shared power to vote or to direct the vote 2,162,392
           
      (iii) Sole power to dispose or to direct the disposition of 0
           
      (iv) Shared power to dispose or to direct the disposition of 2,162,392
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       

    Item 10. Certification:

     

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

     

     

    CUSIP NO. 45779A846 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
         
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
         
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $NSPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kester Thomas J bought $74,998 worth of shares (30,991 units at $2.42), increasing direct ownership by 8% to 420,758 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    CEO and President Slosman Marvin bought $24,999 worth of shares (10,330 units at $2.42), increasing direct ownership by 0.43% to 2,420,866 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:21 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $50,000 worth of shares (20,661 units at $2.42) (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:19 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NSPR
    SEC Filings

    View All

    New insider Cohen Raymond W claimed ownership of 48,387 shares (SEC Form 3)

    3 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:37:46 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Kester Thomas J bought $74,998 worth of shares (30,991 units at $2.42), increasing direct ownership by 8% to 420,758 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    CEO and President Slosman Marvin bought $24,999 worth of shares (10,330 units at $2.42), increasing direct ownership by 0.43% to 2,420,866 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:21 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors

    Biobeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors. Biobeat developed and has received FDA clearance for an easy-to-apply "patch" device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. "We welcome

    8/21/25 7:00:00 AM ET
    $KMTS
    $NSPR
    $RXST
    Medical/Dental Instruments
    Health Care
    Ophthalmic Goods

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

    ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system,

    8/4/25 8:05:00 AM ET
    $AXNX
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care
    Ophthalmic Goods

    SEC Form EFFECT filed by InspireMD Inc.

    EFFECT - InspireMD, Inc. (0001433607) (Filer)

    8/15/25 12:15:23 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by InspireMD Inc.

    424B3 - InspireMD, Inc. (0001433607) (Filer)

    8/14/25 4:20:37 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by InspireMD Inc.

    S-3 - InspireMD, Inc. (0001433607) (Filer)

    8/6/25 4:06:08 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

    MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the "Effective Date"). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years. Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotic

    6/3/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

    MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

    11/25/24 4:05:00 PM ET
    $ABT
    $NSPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Second Quarter 2025 Financial Results

    MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of

    7/22/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports First Quarter 2025 Financial Results

    MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

    5/9/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care